|
E1: (b)(6).Complainant country: taiwan, province of china.Based on the available information, this event is deemed to be a reportable malfunction.To date no additional information has been received.Should additional information become available, a follow-up report will be submitted.Fda registration number reporting site: 1049092.Manufacturing site: 1000317571.
|
|
Additional information - this emdr is being submitted to include the below: d9: device available for evaluation has been selected as yes & date returned to mfg was added as well.H3: device evaluated by manufacturer? has been selected as yes.H6: investigation results under type of investigation, investigation findings, investigation conclusions.H11: investigation summary.Complaint: foreign matter within product, sterile products (e.G.Metal contamination in dressings, particulates within fluids, gels etc).Region: taiwan.Product / system application product (sap): 1704595 aquacel extra 15x15cm (1x5pk) ster nai.Lot: 5a05302.Date of manufacture: 28jan2025.Complaint reference: record in database.Sterilisation: steris gamma run id (b)(4) ¿ 01feb2025.Batch size: (b)(4) secondary units ((b)(4) primary units).A complaint in database was received from taiwan reporting a foreign body identified during inbound inspection of the product.The complaint relates to material 1704595 ¿ lot 5a05302, manufactured on 28jan2025 and sterilized under steris gamma run id (b)(4) on 01feb2025.The complaint report indicates that one primary unit was affected from a batch size of (b)(4) secondary units ((b)(4) primary units).One photograph was provided by the complainant to demonstrate the reported mark observed on the product.The image shows a black mark visible on the aquacel extra primary pack/dressing surface.The impacted product was returned to convatec for evaluation, and the physical sample was received on 21jan2026.Evaluation of the returned sample enabled a detailed inspection of the affected dressing.Visual examination determined that the reported black mark was not foreign contamination.The mark was identified as excess print transfer associated with the unique device identification / unique identifier (udi) printing on the primary pack, resulting in a visible ink artefact on the product surface.No evidence of foreign particulate contamination or extraneous material was identified during the inspection of the returned sample.A batch record review (brr) was conducted for lot 5a05302.All quality control inspections and final release activities were completed and recorded as acceptable.No material-related or contamination-related issues were documented during manufacturing.¿ good manufacturing practice (gmp) compliance records confirm appropriate gowning, environmental monitoring, and adherence to approved manufacturing procedures during the production period.No corrective and preventive actions (capa) s or nonconformances were raised in relation to the production of order (b)(4), and no process deviations or contamination-related events were identified for lot 5a05302.A review of complaint history identified one additional complaint in database associated with lot 5a05302 within the previous 12-month period.However, the malfunction assigned to that complaint was not related to the issue reported in this case.A broader material-level review for material 1704595 (aquacel extra 15x15cm (1x5pk) ster nai) identified no additional complaints associated with malfunction foreign matter within product over the previous 12-month review period.Evaluation of the returned sample confirmed that the reported mark was not foreign contamination, but rather excess print transfer associated with the unique device identification / unique identifier (udi) printing on the primary pack.Based on the criteria defined within work instructions (wi) complaint risk assessment, the event does not represent an increased risk to patient safety, device performance, or regulatory compliance.There was no evidence of a systemic failure mode, recurring defect signature, or adverse trend associated with this issue.In alignment with work instructions (wi) complaint investigation requirements, corrective and preventive actions (capa) were not required, as the investigation did not identify a manufacturing process deviation or recurring defect pattern.The batch remains within specification and acceptable quality limits, and the issue is considered an isolated occurrence.The complaint will continue to be monitored through routine complaint trending and the post market product monitoring review process, standard operating procedure (sop).Fda registration number: reporting site: 1049092.Manufacturing site: 1000317571.
|